Needham & Company LLC Reiterates Hold Rating for Envista (NYSE:NVST)

Envista (NYSE:NVST)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a report released on Tuesday,Benzinga reports.

Other equities research analysts have also recently issued reports about the company. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Piper Sandler boosted their price objective on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley boosted their price objective on Envista from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Robert W. Baird boosted their price objective on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Finally, Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and boosted their price objective for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.21.

Envista Trading Up 0.1 %

NYSE NVST opened at $20.69 on Tuesday. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of -3.19, a PEG ratio of 1.27 and a beta of 1.34. Envista has a one year low of $15.15 and a one year high of $23.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The business’s fifty day moving average is $20.23 and its 200-day moving average is $19.63.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts predict that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Envista during the third quarter worth about $31,000. Huntington National Bank grew its holdings in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after purchasing an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after purchasing an additional 728 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.